Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.

von Wartburg M, Raymond V, Paradis PE.

Int J Clin Pract. 2014 May;68(5):639-46. doi: 10.1111/ijcp.12363. Epub 2014 Jan 29.

PMID:
24472120
2.

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study.

Shinder GA, Paradis PE, Posman M, Mishagina N, Guay MP, Linardos D, Batist G.

BMC Health Serv Res. 2012 Oct 29;12:370. doi: 10.1186/1472-6963-12-370.

3.

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.

Manjunath R, Paradis PE, Parisé H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E.

Neurology. 2012 Oct 30;79(18):1908-16. doi: 10.1212/WNL.0b013e318271f77e. Epub 2012 Oct 17.

PMID:
23077014
5.

Economic burden associated with the use of generic antiepileptic drugs in the United States.

Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Labiner DM.

Epilepsy Behav. 2010 Aug;18(4):437-44. doi: 10.1016/j.yebeh.2010.05.015. Epub 2010 Jun 30.

PMID:
20580619
6.

Generic antiepileptic drugs and associated medical resource utilization in the United States.

Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Helmers SL.

Neurology. 2010 May 18;74(20):1566-74. doi: 10.1212/WNL.0b013e3181df091b. Epub 2010 Apr 14.

PMID:
20393142
7.

ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management.

Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

Healthc Q. 2010;13(4):30-9.

PMID:
24953807
8.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.

Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Review.

PMID:
19663636
9.

The risks and costs of multiple-generic substitution of topiramate.

Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Neurology. 2009 Jun 16;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300.

PMID:
19528520
10.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Curr Med Res Opin. 2009 Jul;25(7):1793-805. doi: 10.1185/03007990903044374.

PMID:
19505202
11.

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.

LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

Neurology. 2008 May 27;70(22 Pt 2):2179-86. doi: 10.1212/01.wnl.0000313154.55518.25.

PMID:
18505997
12.

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

Curr Med Res Opin. 2008 Apr;24(4):1069-81. doi: 10.1185/030079908X280572 . Epub 2008 Feb 29.

PMID:
18315941
13.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.

Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY.

Dis Manag. 2007 Aug;10(4):216-25.

PMID:
17718660
14.

Supplemental Content

Loading ...
Support Center